Kazia Therapeutics Limited (KZIA)

Market Cap	138.38M +3,140.6%
Revenue (ttm)	1.27M -24.2%
Net Income	-15.21M
EPS	-6.82
Shares Out	11.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	206,361
Open	12.40
Previous Close	12.56
Day's Range	11.72 - 12.55
52-Week Range	3.24 - 17.40
Beta	2.23
Analysts	Buy
Price Target	21.34 (+76.22%)
Earnings Date	Jun 4, 2026

About KZIA

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain met...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 6, 1999
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: KZIA
• Website: https://www.kaziatherapeutics.com

Financial Performance

In fiscal year 2025, Kazia Therapeutics's revenue was 1.83 million, a decrease of -26.28% compared to the previous year's 2.48 million. Losses were -20.70 million, -22.69% less than in 2024.

Financial numbers in AUD

Analyst Summary

According to 3 analysts, the average rating for KZIA stock is "Buy." The 12-month stock price target is $21.34, which is an increase of 76.22% from the latest price.

Price Target

$21.34

(76.22% upside)

Analyst Consensus: Buy